

Antibody-drug Conjugates-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/A5C38F60B83EN.html>

Date: January 2018

Pages: 147

Price: US\$ 3,480.00 (Single User License)

ID: A5C38F60B83EN

Abstracts

Report Summary

Antibody-drug Conjugates-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antibody-drug Conjugates industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Antibody-drug Conjugates 2013-2017, and development forecast 2018-2023

Main market players of Antibody-drug Conjugates in EMEA, with company and product introduction, position in the Antibody-drug Conjugates market

Market status and development trend of Antibody-drug Conjugates by types and applications

Cost and profit status of Antibody-drug Conjugates, and marketing status

Market growth drivers and challenges

The report segments the EMEA Antibody-drug Conjugates market as:

EMEA Antibody-drug Conjugates Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Antibody-drug Conjugates Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Seattle Genetics technology
ImmunoGen technology
Immunomedics technology

EMEA Antibody-drug Conjugates Market: Application Segment Analysis (Consumption
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

IgG1 antibodies
HER2 antibodies

EMEA Antibody-drug Conjugates Market: Players Segment Analysis (Company and
Product introduction, Antibody-drug Conjugates Sales Volume, Revenue, Price and
Gross Margin):

F. Hoffmann-La Roche
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Agensys
ALMAC Group
Ambrx
Astellas Pharma

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF ANTIBODY-DRUG CONJUGATES

- 1.1 Definition of Antibody-drug Conjugates in This Report
- 1.2 Commercial Types of Antibody-drug Conjugates
 - 1.2.1 Seattle Genetics technology
 - 1.2.2 ImmunoGen technology
 - 1.2.3 Immunomedics technology
- 1.3 Downstream Application of Antibody-drug Conjugates
 - 1.3.1 IgG1 antibodies
 - 1.3.2 HER2 antibodies
- 1.4 Development History of Antibody-drug Conjugates
- 1.5 Market Status and Trend of Antibody-drug Conjugates 2013-2023
 - 1.5.1 EMEA Antibody-drug Conjugates Market Status and Trend 2013-2023
 - 1.5.2 Regional Antibody-drug Conjugates Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Antibody-drug Conjugates in EMEA 2013-2017
- 2.2 Consumption Market of Antibody-drug Conjugates in EMEA by Regions
 - 2.2.1 Consumption Volume of Antibody-drug Conjugates in EMEA by Regions
 - 2.2.2 Revenue of Antibody-drug Conjugates in EMEA by Regions
- 2.3 Market Analysis of Antibody-drug Conjugates in EMEA by Regions
 - 2.3.1 Market Analysis of Antibody-drug Conjugates in Europe 2013-2017
 - 2.3.2 Market Analysis of Antibody-drug Conjugates in Middle East 2013-2017
 - 2.3.3 Market Analysis of Antibody-drug Conjugates in Africa 2013-2017
- 2.4 Market Development Forecast of Antibody-drug Conjugates in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Antibody-drug Conjugates in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Antibody-drug Conjugates by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Antibody-drug Conjugates in EMEA by Types
 - 3.1.2 Revenue of Antibody-drug Conjugates in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe

- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Antibody-drug Conjugates in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Antibody-drug Conjugates in EMEA by Downstream Industry
- 4.2 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Africa
- 4.3 Market Forecast of Antibody-drug Conjugates in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Antibody-drug Conjugates Downstream Industry Situation and Trend Overview

CHAPTER 6 ANTIBODY-DRUG CONJUGATES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Antibody-drug Conjugates in EMEA by Major Players
- 6.2 Revenue of Antibody-drug Conjugates in EMEA by Major Players
- 6.3 Basic Information of Antibody-drug Conjugates by Major Players
 - 6.3.1 Headquarters Location and Established Time of Antibody-drug Conjugates Major Players
 - 6.3.2 Employees and Revenue Level of Antibody-drug Conjugates Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 ANTIBODY-DRUG CONJUGATES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 F. Hoffmann-La Roche

7.1.1 Company profile

7.1.2 Representative Antibody-drug Conjugates Product

7.1.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche

7.2 Seattle Genetics

7.2.1 Company profile

7.2.2 Representative Antibody-drug Conjugates Product

7.2.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Seattle Genetics

7.3 Takeda Pharmaceuticals

7.3.1 Company profile

7.3.2 Representative Antibody-drug Conjugates Product

7.3.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals

7.4 AbbVie

7.4.1 Company profile

7.4.2 Representative Antibody-drug Conjugates Product

7.4.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbbVie

7.5 AbGenomics

7.5.1 Company profile

7.5.2 Representative Antibody-drug Conjugates Product

7.5.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbGenomics

7.6 ADC Therapeutics

7.6.1 Company profile

7.6.2 Representative Antibody-drug Conjugates Product

7.6.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ADC Therapeutics

7.7 Agensys

7.7.1 Company profile

7.7.2 Representative Antibody-drug Conjugates Product

7.7.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Agensys

7.8 ALMAC Group

7.8.1 Company profile

7.8.2 Representative Antibody-drug Conjugates Product

7.8.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ALMAC Group

7.9 Ambrx

7.9.1 Company profile

7.9.2 Representative Antibody-drug Conjugates Product

7.9.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Ambrx

7.10 Astellas Pharma

7.10.1 Company profile

7.10.2 Representative Antibody-drug Conjugates Product

7.10.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Astellas Pharma

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY-DRUG CONJUGATES

8.1 Industry Chain of Antibody-drug Conjugates

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY-DRUG CONJUGATES

9.1 Cost Structure Analysis of Antibody-drug Conjugates

9.2 Raw Materials Cost Analysis of Antibody-drug Conjugates

9.3 Labor Cost Analysis of Antibody-drug Conjugates

9.4 Manufacturing Expenses Analysis of Antibody-drug Conjugates

CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTIBODY-DRUG CONJUGATES

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Antibody-drug Conjugates-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/A5C38F60B83EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A5C38F60B83EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970